EPO Enlarged Board of Appeal repeats obligation to raise objections in time

In Insights, Uncategorized

1 February, 2012

Last week, the European Patent Office released two new decisions by the Enlarged Board of Appeal on petitions for review, R 2/11 and R 10/11. Both the underlying petitions were based on what the petitioners regarded as fundamental procedural defects before respective Boards of Appeal 3.2.04 and 3.2.03.

Both cases are appeals from opposition proceedings. In R 10/11, the Board had refused to discuss late-filed requests for claim amendments. In R 2/11, an Opponent had been allowed to make an oral presentation of the technical background. The Proprietor was taken by surprise by the Opponent’s presentation; he had not prepared his counterarguments, he could hear at least one half-truth in the presentation – and to his great horror, the presentation had a very convincing effect on the Board!                          

However, the Enlarged Board did not go into the details of neither case, but noted only that neither of the petitioners had raised an objection in respect of the procedural defect in due time. Indeed, as provided by Rule 106 EPC, the Enlarged Board shall not deal with a purported procedural defect unless the Board of Appeal has been made aware of it during the appeal proceedings.

Looking at the decisions on petitions handed down by the Enlarged Board in 2010 and 2011, we see that a breach of Rule 106 EPC was a sufficient ground for rejection in 7 out of 34 non-withdrawn petitions (R 3/11, R 7/11, R 17/10, R 1/10, R 6/10, R 7/10, R 9/09). In other words, appeal proceedings are no place for silent suffering; if you are unhappy with the way the proceedings are conducted, you should voice your concern and make sure it gets written down in the minutes.

Anders Hansson, European Patent Attorney

You may also be interested in:

Companies with IP generate at least 23.8% more revenue according to latest EU report

The report ‘The Intellectual Property Rights and Firm Performance in the European Union’ was published last month and analyses

Read more...

European Commission reports show misuse of divisionals can in itself contravene EU law

In November last year, I was interviewed about the European Commission’s €462.6 million fine against pharmaceutical giant Teva and

Read more...

IP Enforcement Strategies: Combating Counterfeiting in Southeast Asia and China

Counterfeiting remains among the most significant threats to intellectual property rights globally, particularly in Southeast Asia and China. These

Read more...

Mobile Sliding Menu